Home   |   
 NACDS Foundation   |   
 Contact NACDSF   |   
 Contact RxSchool   |   
 Log In   


 Implications of Medicaid Reform for Community Retail Pharmacy
  Course Information Back to Catalog   


This lesson is supported by:

 

Program Description

Over the course of this year, pharmacists have become very familiar with the Medicare Modernization Act, which created the new Medicare Part D drug benefit. Pharmacists will soon be hearing more about the recently enacted Deficit Reduction Act (DRA) of 2005,[1] which will modify the way Medicaid pays for generic drugs, create greater transparency in the pharmaceutical marketplace, and make other changes in how states will provide healthcare services for low-income individuals. This program describes the changes brought on by the DRA and discusses implications for community pharmacies and patients.

[1] Public Law No. 109-171

by John M. Coster, Ph.D., R.Ph.

John Coster, Ph.D., R.Ph., is Vice President of Policy and Programs with the National Association of Chain Drug Stores. He is responsible for policy relating to federal and state health care programs such as Medicare and Medicaid, as well as federal regulatory issues working closely with the Food and Drug Administration (FDA). He is a 1984 graduate of St. John’s University College of Pharmacy in New York and received his Masters and Ph.D. in Health Policy from the University of Maryland.

Faculty Disclosure

The NACDS Foundation has a conflict of interest policy that requires course faculty to disclose any real or apparent commercial financial affiliations related to the content of their presentations/materials.  The author of this program has no conflicts of interest.

Disclaimer

The author, sponsor, and publisher of this continuing education program have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available knowledge at the time of accreditation of this continuing education program.

Learning Objectives

At the conclusion of this program, participants will be better able to:

  • Understand the implications on community pharmacy of the public release of AMP (average manufacturer’s price) data as well as the upcoming reduction in generic drug payments to pharmacists; 
  • Explain AMP and FULs (Federal Upper Limits) for generic drugs; and
  • Understand the changes that states will be able to make to Medicaid benefit packages and cost sharing amounts under DRA.

Target Audience

This program is appropriate for pharmacists in any practice setting.

Technologies Used

Monograph Monograph
Price: FREE!
ACPE Accreditation
The National Association of Chain Drug Stores (NACDS) Foundation is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This home study web activity has been assigned a maximum of 2 credit hours (0.2 CEU) and the ACPE UPN: 206-000-06-017-H04.

This accreditation expires on 11/02/2009.
 
To receive educational credit, participants must complete an online evaluation form and pass the online assessment with a score of 70% or better. If you do not receive a minimum score of 70% or better, you are permitted 1 retake(s). After passing the assessment, you can view, print and track your statements of credit online. There is no fee to participate in this activity.
The material presented here does not reflect the views of Pharmacy Choice, Inc., RxSchool, or the companies providing educational content. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
This lesson is supported by: